Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients
Lung cancer, including non-small cell lung carcinoma (NSCLC), is the most frequently diagnosed cancer. It is also the leading cause of cancer-related mortality worldwide because of its late diagnosis and its resistance to therapies. Therefore, the identification of biomarkers for early diagnosis, pr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-05-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fgene.2019.00390/full |
| _version_ | 1819048133025333248 |
|---|---|
| author | Florence de Fraipont Florence de Fraipont Sylvie Gazzeri William C. Cho Beatrice Eymin |
| author_facet | Florence de Fraipont Florence de Fraipont Sylvie Gazzeri William C. Cho Beatrice Eymin |
| author_sort | Florence de Fraipont |
| collection | DOAJ |
| description | Lung cancer, including non-small cell lung carcinoma (NSCLC), is the most frequently diagnosed cancer. It is also the leading cause of cancer-related mortality worldwide because of its late diagnosis and its resistance to therapies. Therefore, the identification of biomarkers for early diagnosis, prognosis, and monitoring of therapeutic response is urgently needed. Liquid biopsies, especially blood, are considered as promising tools to detect and quantify circulating cancer biomarkers. Cell-free circulating tumor DNA has been extensively studied. Recently, the possibility to detect and quantify RNAs in tumor biopsies, notably circulating cell-free RNAs, has gained great attention. RNA alternative splicing contributes to the proteome diversity through the biogenesis of several mRNA splice variants from the same pre-mRNA. Circular RNA (circRNA) is a new class of RNAs resulting from pre-mRNA back splicing. Owing to the development of high-throughput transcriptomic analyses, numerous RNA splice variants and, more recently, circRNAs have been identified and found to be differentially expressed in tumor patients compared to healthy controls. The contribution of some of these RNA splice variants and circRNAs to tumor progression, dissemination, or drug response has been clearly demonstrated in preclinical models. In this review, we discuss the potential of circRNAs and mRNA splice variants as candidate biomarkers for the prognosis and the therapeutic response of NSCLC in liquid biopsies. |
| first_indexed | 2024-12-21T11:11:24Z |
| format | Article |
| id | doaj.art-8818850e4656462d9c11a146cf2b2cf0 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-12-21T11:11:24Z |
| publishDate | 2019-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-8818850e4656462d9c11a146cf2b2cf02022-12-21T19:06:04ZengFrontiers Media S.A.Frontiers in Genetics1664-80212019-05-011010.3389/fgene.2019.00390451325Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer PatientsFlorence de Fraipont0Florence de Fraipont1Sylvie Gazzeri2William C. Cho3Beatrice Eymin4INSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, University Grenoble Alpes, Grenoble, FranceGrenoble Hospital, La Tronche, FranceINSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, University Grenoble Alpes, Grenoble, FranceDepartment of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong KongINSERM U1209, CNRS UMR5309, Institute for Advanced Biosciences, University Grenoble Alpes, Grenoble, FranceLung cancer, including non-small cell lung carcinoma (NSCLC), is the most frequently diagnosed cancer. It is also the leading cause of cancer-related mortality worldwide because of its late diagnosis and its resistance to therapies. Therefore, the identification of biomarkers for early diagnosis, prognosis, and monitoring of therapeutic response is urgently needed. Liquid biopsies, especially blood, are considered as promising tools to detect and quantify circulating cancer biomarkers. Cell-free circulating tumor DNA has been extensively studied. Recently, the possibility to detect and quantify RNAs in tumor biopsies, notably circulating cell-free RNAs, has gained great attention. RNA alternative splicing contributes to the proteome diversity through the biogenesis of several mRNA splice variants from the same pre-mRNA. Circular RNA (circRNA) is a new class of RNAs resulting from pre-mRNA back splicing. Owing to the development of high-throughput transcriptomic analyses, numerous RNA splice variants and, more recently, circRNAs have been identified and found to be differentially expressed in tumor patients compared to healthy controls. The contribution of some of these RNA splice variants and circRNAs to tumor progression, dissemination, or drug response has been clearly demonstrated in preclinical models. In this review, we discuss the potential of circRNAs and mRNA splice variants as candidate biomarkers for the prognosis and the therapeutic response of NSCLC in liquid biopsies.https://www.frontiersin.org/article/10.3389/fgene.2019.00390/fullcancer biomarkerscircular RNAsliquid biopsieslung cancerRNA splice variants |
| spellingShingle | Florence de Fraipont Florence de Fraipont Sylvie Gazzeri William C. Cho Beatrice Eymin Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients Frontiers in Genetics cancer biomarkers circular RNAs liquid biopsies lung cancer RNA splice variants |
| title | Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients |
| title_full | Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients |
| title_fullStr | Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients |
| title_full_unstemmed | Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients |
| title_short | Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients |
| title_sort | circular rnas and rna splice variants as biomarkers for prognosis and therapeutic response in the liquid biopsies of lung cancer patients |
| topic | cancer biomarkers circular RNAs liquid biopsies lung cancer RNA splice variants |
| url | https://www.frontiersin.org/article/10.3389/fgene.2019.00390/full |
| work_keys_str_mv | AT florencedefraipont circularrnasandrnasplicevariantsasbiomarkersforprognosisandtherapeuticresponseintheliquidbiopsiesoflungcancerpatients AT florencedefraipont circularrnasandrnasplicevariantsasbiomarkersforprognosisandtherapeuticresponseintheliquidbiopsiesoflungcancerpatients AT sylviegazzeri circularrnasandrnasplicevariantsasbiomarkersforprognosisandtherapeuticresponseintheliquidbiopsiesoflungcancerpatients AT williamccho circularrnasandrnasplicevariantsasbiomarkersforprognosisandtherapeuticresponseintheliquidbiopsiesoflungcancerpatients AT beatriceeymin circularrnasandrnasplicevariantsasbiomarkersforprognosisandtherapeuticresponseintheliquidbiopsiesoflungcancerpatients |